Drug Profile
RGSH 4K
Alternative Names: Autologous cancer vaccine - Regeneus; RGSH4K; RGSH4K-tumour-cell-vaccineLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Regeneus ltd
- Class Adjuvants; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Australia (Intradermal, Injection)
- 23 Aug 2018 Regeneus terminates a phase I trial in Solid tumours (Late-stage disease) in Australia (Intradermal) (ACTRN12615000516583)
- 30 Jul 2018 RGSH 4K is still in phase I trials for Solid tumours in Australia